10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Golimumab

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Golimumab

Golimumab

Class : A

Show all info

Print

Contact us

  1. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - SIMPONI (golimumab). Food and Drug Administration [www]. [cited 2009-04-24].

  2. Xu ZH, Lee H, Vu T, Hu C, Yan H, Baker D et al. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. Int J Clin Pharmacol Ther. 2010;48:596-607.

  3. Inman RD, Davis JC, Heijde Dv, Diekman L, Sieper J, Kim SI et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402-12.

  4. Simponi (golimumab). Summary of Product Characteristics. European Medicines Ageny; 2016.

  5. Dasgupta B, Combe B, Louw I, Wollenhaupt J, Zerbini CA, Beaulieu A et al. Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes. Arthritis Care Res (Hoboken). 2014;66:1799-807.

  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.]

  1. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - SIMPONI (golimumab). Food and Drug Administration [www]. [cited 2009-04-24].
  2. Xu ZH, Lee H, Vu T, Hu C, Yan H, Baker D et al. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. Int J Clin Pharmacol Ther. 2010;48:596-607.
  3. Inman RD, Davis JC, Heijde Dv, Diekman L, Sieper J, Kim SI et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402-12.
  4. Simponi (golimumab). Summary of Product Characteristics. European Medicines Ageny; 2016.
  5. Dasgupta B, Combe B, Louw I, Wollenhaupt J, Zerbini CA, Beaulieu A et al. Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes. Arthritis Care Res (Hoboken). 2014;66:1799-807.
  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.]